Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis - sprookjes - yvandenbroek - TriplyDB

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

http://www.wikidata.org/entity/Q28217179

about

sameAs

Coccidioidomycosis--a fungal disease of the Americas Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections Voriconazole versus amphotericin B in cancer patients with neutropenia Novel perspectives on mucormycosis: pathophysiology, presentation, and management.Voriconazole therapeutic drug monitoring.Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome.Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations Fungal infections of the orbit Modulation of Host Angiogenesis as a Microbial Survival Strategy and Therapeutic Target Optimizing Outcomes in Immunocompromised Hosts: Understanding the Role of Immunotherapy in Invasive Fungal Diseases Invasive mold infections in solid organ transplant recipients Recommendations for the Treatment of Invasive Fungal Infections in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-1)Pneumonia in the neutropenic cancer patient How to manage aspergillosis in non-neutropenic intensive care unit patients Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications Acetazolamide-based fungal chitinase inhibitors Structure of N-myristoyltransferase from Aspergillus fumigatus Anti-Immune Strategies of Pathogenic Fungi Antifungal Therapy in Hematopoietic Stem Cell Transplant Recipients Fundament and Prerequisites for the Application of an Antifungal TDM Service Comparison of echinocandin antifungals Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)Invasive aspergillosis in the intensive care unit Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin Genetic variation in plant CYP51s confers resistance against voriconazole, a novel inhibitor of brassinosteroid-dependent sterol biosynthesis Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing Utilization and comparative effectiveness of caspofungin and voriconazole early after market approval in the U.S Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions Epidemiology of invasive candidiasis: a persistent public health problem A computational model of invasive aspergillosis in the lung and the role of iron.Aspergillus infections in transplant and non-transplant surgical patients Fatal clinical course of probable invasive pulmonary aspergillosis with influenza B infection in an immunocompetent patient.Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality Aspergillus endocarditis: a case of near complete left ventricular outflow obstruction.

P2860

Q21144726-0ABF7E3A-8660-4DB2-9F55-C6E68FFF72B9 Q24200304-1C80D00F-529A-43BC-AC20-56CE6E448BDA Q24239978-5B0361A9-093B-47BD-9B9D-1C0953268430 Q24243629-9D783D20-6B91-4A54-9DB3-F7A5D9B39AF3 Q24244950-AF4974DC-372B-4179-B76D-727BAFFF7E9D Q24530554-4D1F67D5-F946-4888-8319-959EECAD2E2E Q24542411-CCF6EDB2-0BFA-47C6-9019-6BABB77E7B4C Q24811601-1EE321E5-97E1-4153-BF1F-0CADCEDEA342 Q25257632-DB90B955-23DA-458D-8F03-6D90BCCDC063 Q26744426-460229BB-32AA-4015-9B58-76CFA383F329 Q26748251-AB767809-5584-45CF-BA64-305E8684E274 Q26774692-82D4B5D6-B95F-4F00-A71A-3A01BCE894C4 Q26823811-687F3DB8-8D9D-4AA4-AE84-4CAAC9AFFA36 Q26824260-E571FC5B-4BC1-41BF-9EC9-808457C6F1FE Q26827758-74FD24D6-9433-493E-84DA-64E1ACD93F11 Q26999448-4EA4BB32-018E-47E2-998B-5A3C28FCA39F Q27009221-97F8114D-F13A-4A20-BD54-F479F5556B0C Q27025299-6E5C9645-02D3-4991-B215-779193F30283 Q27665555-1D2147A8-ABE9-404E-8D65-1F3262FD2D19 Q27700103-05198A93-C359-453F-A642-E4DF1D68963F Q28071716-A8359C27-B946-4D5D-AEE3-49B2522B7005 Q28080147-AE508793-20CB-4C5F-A1A5-BF74EB1B62E2 Q28085352-653E80D0-DA04-48FE-A8E0-A9B0D4AF66BC Q28273738-D59D6FEC-12C3-4891-B16F-76B4AEAA3AFA Q28277029-A5763110-7D84-4C1E-AAFC-FB9E7A1CE7B9 Q28298468-9C5C3F4E-7DDB-4FC3-8C61-7BE3832E1EFC Q28306909-571C5715-E497-4DBA-8D14-72B19950847F Q28475818-F72A599A-70AC-4B26-B8D3-BD1243C3C734 Q28485119-6A47FBA8-213C-46CD-B25F-FE7F3345E297 Q28485433-C0563709-4EB9-4D91-A518-2B1BAD51CCB6 Q28538618-ED5ED8FD-EFA3-4419-A14A-DBE6E7AFC8DD Q28540254-A65EDA33-CC60-4FD9-BA7C-68D466536526 Q28727508-5A73FE8C-68C0-4413-8105-F04660459CB5 Q29399166-6BAD4307-3069-4B9E-BA26-26838925558D Q29616758-5B6999B8-4416-4766-A14C-7C95CF3B5D22 Q30276951-D66A3AE1-0DAA-4CBF-B848-0C9296990C70 Q30361624-36582F73-A2B4-446C-91F8-9B8C1D899433 Q30367762-6FE7C656-AFEC-4BF0-9744-1090E9B5277D Q30438524-E1EC575C-B09B-46F4-A795-D505BE9AAC6C Q30514075-DDA64381-0B21-4DF0-83E9-629E2A8F231B

P2860

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

http://www.wikidata.org/entity/Q28217179

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

@ast

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

@en

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

@nl

type

label

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

@ast

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

@en

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

@nl

prefLabel

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

@ast

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

@en

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

@nl

P1433

Q28217179-1712FAEF-E4BA-4E18-934B-99D0AE219E1B

P1476

Q28217179-DB60CD66-52E6-49B7-AC12-EEB375597157

P2093

Q28217179-00881892-2A08-4EF1-AE40-6D5131E24A4B

Q28217179-055DD87A-D03E-4A62-98EC-DCC5AAE4F62F

Q28217179-15F6526E-ACBF-4B5F-9420-0D7D3F12EEED

Q28217179-4F7B9BC6-140D-4E58-98F1-9AFE0ACA4C2C

Q28217179-52AF79F6-0AAD-4992-8BB1-570B5D04D611

Q28217179-63733F54-6A85-4573-952E-D5509AFF5EBB

Q28217179-69381891-007D-44EE-A748-6056F817863E

Q28217179-6C61633F-D758-498E-8DA0-DECFF8FCE969

Q28217179-72E688FA-2E6A-47EB-B511-7E852BD084B2

Q28217179-81098EA5-6362-467F-B8A9-DA4B29996264

P304

Q28217179-620F8FDE-C9AB-4607-B53E-B9A8619DAD14

P31

Q28217179-564847FF-063F-4C0C-8B05-2DE7AEFA12F5

P3181

Q28217179-5CC80618-2C3C-4878-B879-38AAFA526C5B

P356

Q28217179-706E8E97-6034-4DDF-870A-FE7862BD1DB8

P407

Q28217179-5A7AB3B4-1A0E-4826-B17C-67A1F6F530CC

P433

Q28217179-81248BB0-FC56-48D2-A273-97B1D493C702

P478

Q28217179-BB03489F-9E03-4CDD-85EA-F7E3A203AD9B

P50

Q28217179-60E38C1B-C0D8-4555-8272-17CD6A8BBEF3

Q28217179-75FC9E1C-7502-47CC-A9FA-F50561F97E35

Q28217179-AB837795-6F3A-4685-BB75-6D50C38B8978

P577

Q28217179-D138EEB7-EB68-41DD-A018-B84AAC2D99E9

P698

Q28217179-8CB2E066-5700-4D57-B3A2-E44FF9D8048F

P921

Q28217179-E4F49E36-9933-45CA-A4A9-30FDF11E7105

P3181

P356

P1433

The New England Journal of Medicine

P1476

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

@en

P2093

Ben de Pauw

http://www.w3.org/2001/XMLSchema#string

Christine Durand

http://www.w3.org/2001/XMLSchema#string

Denis Caillot

http://www.w3.org/2001/XMLSchema#string

Eckhard Thiel

http://www.w3.org/2001/XMLSchema#string

Haran T Schlamm

http://www.w3.org/2001/XMLSchema#string

John E Bennett

http://www.w3.org/2001/XMLSchema#string

John R Wingard

http://www.w3.org/2001/XMLSchema#string

Jörg-W Oestmann

http://www.w3.org/2001/XMLSchema#string

Kieren A Marr

http://www.w3.org/2001/XMLSchema#string

Michael R Hodges

http://www.w3.org/2001/XMLSchema#string

P304

408-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1199541

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA020191

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

347

http://www.w3.org/2001/XMLSchema#string

P50

Olivier Lortholary

David W. Denning

Raoul Herbrecht

P577

2002-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12167683

http://www.w3.org/2001/XMLSchema#string

P921